i-manager Publications

A Review Based on the Synthesis of Isoniazid Derivatives and their Pharmacological Activities

Adithya G.*, Arya S. Kumar**, Anoopa John L.***

*-*** The Dale View College of Pharmacy and Research Centre, Poovachal, Thiruvananthapuram, Kerala, India.

Periodicity:January - June'2024

Abstract

Tuberculosis (TB), which has afflicted humanity for thousands of years, is a worldwide pandemic disease caused mainly by Mycobacterium tuberculosis. The first-line treatment for an active TB infection is the antibiotic isoniazid (INH). Different derivatives of isoniazid are prepared by changing the chemical structure and introducing different moieties. In this review, the aim is to encapsulate different methods for the synthesis of isoniazid derivatives and their pharmacological activities. Through this exploration, insights into the potential avenues for the development of more effective treatments against TB are offered.

Keywords

Isoniazid, Mycobacterium Tuberculosis, Mycolic Acid, Pulmonary TB, Haemoptysis, Antimycobacterial, Anticancer.

How to Cite this Article?

Adithya, G., Kumar, A. S., and John, L. A. (2024). A Review Based on the Synthesis of Isoniazid Derivatives and their Pharmacological Activities. Dale View's Journal of Clinical Pharmacology and Pharmacotherapeutics, 1(1), 8-14.

References

[1]. Zaman, K. (2010). Tuberculosis: A global health problem. Journal of Health, Population, and Nutrition, 28(2), 111.

[2]. Chadha, V. K. (2009). Progress towards millennium development goals for TB control in seven Asian countries. Indian Journal of Tuberculosis, 56(1), 30-43.

[3]. Hearn, M. J., Cynamon, M. H., Chen, M. F., Coppins, R., Davis, J., Kang, H. J. O., ... & Wilson, R. (2009). Preparation and antitubercular activities in vitro and in vivo of novel Schiff bases of isoniazid. European journal of Medicinal Chemistry, 44(10), 4169-4178.

[4]. Blumberg, H. M., Burman, W. J., Chaisson, R. E., & Daley, C. L. (2003). American thoracic society/centers for disease control and prevention/infectious diseases society of America: treatment of tuberculosis. American Journal of Respiratory and Critical Care Medicine, 167(4), 603.

[5]. Britannica. (2017). Isoniazid: Drug.

[6]. Bedia, K. K., Elçin, O., Seda, U., Fatma, K., Nathaly, S., Sevim, R., & Dimoglo, A. (2006). Synthesis and characterization of novel hydrazide–hydrazones and the study of their structure–antituberculosis activity. European Journal of Medicinal Chemistry, 41(11), 1253-1261.

[7]. Lei, B., Wei, C. J., & Tu, S. C. (2000). Action mechanism of antitubercular isoniazid: Activation by Mycobacterium tuberculosis KatG, isolation, and characterization of InhA inhibitor. Journal of Biological Chemistry, 275(4), 2520- 2526.

[8]. Tripathi, A., Nadaf, Y. F., Bilehal, D., Nayak, S., & Gaonkar, S. L. (2019). A review on synthesis of isoniazid derivatives and their biological properties. International Journal of Pharmaceutical Research, 11(1), 21-36.

[9]. Gandhi, N., Kumar, A., Kumar, C., Mishra, N., Chaudhary, P., Kaushik, N. K., & Singh, R. (2016). Synthesis, characterization, thermal and biological activity of some novel Cadmium (II)–pyridine and purine base complexes. Main Group Chemistry, 15(1), 35-46.

[10]. Chaudhari, K. S., Patel, H. M., & Surana, S. J. (2017). Pyridines: multidrug-resistant tuberculosis (MDR-TB) inhibitors. Indian Journal of Tuberculosis, 64(2), 119-128.

[11]. Haider, S., Saify, Z. S., & Naz, A. (2015). Synthesis and conformational studies of n'-(3)-5- fluoro-2- oxo-2,3- dihydro-1h-indol-3-ylidene]-3carbohydrazide with specific pharmacophoric features. World Journal of Pharmaceutical Research, 3(7), 342- 351.

[12]. Pahlavani, E., Kargar, H., & Rad, N. S. (2015). A study on antitubercular and antimicrobial activity of isoniazid Derivative. Zahedan Journal of Research in Medical Sciences, 17(7), 1-4.

[13]. Cardoso, S. H., Assis, J. V. D., Almeida, M. V. D., Lourenço, M. C. S., Vicente, F. R., & de Souza, M. V. (2009). Synthesis and antitubercular activity of isoniazid condensed with carbohydrate derivatives. Quimica Nova, 32, 1557-1560.

[14]. Lourenco, M. C., de Souza, M. V., Pinheiro, A. C., Ferreira, M. D. L., Gonçalves, R. S., Nogueira, T. C. M., & Peralta, M. A. (2007). Evaluation of anti-tubercular activity of nicotinic and isoniazid analogues. Arkivoc, 15, 181- 191.

[15]. Sinha, N., Jain, S., Tilekar, A., Upadhayaya, R. S., Kishore, N., Jana, G. H., & Arora, S. K. (2005). Synthesis of isonicotinic acid N′-ar ylidene-N-[2-oxo-2-(4-ar yl-piperazin-1-yl)-ethyl]-hydrazides as antituberculosis agents. Bioorganic & Medicinal Chemistry Letters, 15(6), 1573-1576.

[16]. Kumar, H., Malhotra, D., Sharma, R., Sausville, E., & Malhotra, M. (2011). Synthesis, characterization and evaluation of isoniazid analogues as potent anticancer agents. Pharmacologyonline, 3, 337-343.

[17]. Thomas, A. B., Nanda, R. K., Kothapalli, L. P., & Hamane, S. C. (2016). Synthesis and biological evaluation of Schiff's bases and 2-azetidinones of isonocotinyl hydrazone as potential antidepressant and nootropic agents. Arabian Journal of Chemistry, 9, S79- S90.

If you have access to this article please login to view the article or kindly login to purchase the article

Single Article

	North Americas,UK, Middle East,Europe		India	Rest of world
	USD	EUR	INR	USD-ROW
Pdf	300
Online	300
Pdf & Online	500

ADD TO CART

Options for accessing this content:

If you would like institutional access to this content, please recommend the title to your librarian.
If you already have i-manager's user account: Login above and proceed to purchase the article.
New Users: Please register, then proceed to purchase the article.